Keywords
risk of lymphomas
How to Cite
Abstract
In its course, primary Sjӧgren's syndrome marks an increased risk for developing lymphomas. Compared to healthy population, this risk can reach a 44-fold higher frequency. In the case of a relatively calm course of the disease, a "break" in the clinical picture may occur and the manifestations of malignant lymphoma may develop. However, there are clinical and laboratory abnormalities of varying duration, which, with their summation over time, shorten the path to malignant lymphoproliferation. The identification of groups of patients at an increased risk for developing lymphomas and their follow-up is the basis of the personalized approach in patients with Sjӧgren's syndrome.
References
Brito-Zerón P, Baldini C, Bootsma H et al. Sjӧgren syndrome. Nat. Rev. Dis. Primers. 2016; Vol. 2. P. 16047.
Kassan SS, Thomas TL, Moutsopoulos HM et al. Increased risk of lymphoma in sicca syndrome. Ann Int Med. 1978;89(6):888-92.
Zhang W, Feng S, Yan S et al. Incidence of malignancy in primary Sjӧgren’s syndrome in a Chinese cohort. Rheumatology (Oxford). 2010;49(3),571-577.
Risselada AP, Kruize AA, Goldschmeding R et al. The prognostic value of routinely performed minor salivary gland assessments in primary Sjӧgren’s syndrome. Ann Rheum. Dis. 2014;73(8),1538-1540.
Troppan K, Wenzl K, Neumeister P, Deutsch A. Molecular pathogenesis of MALT lymphoma. Gastroenterol. Res. Pract. (2015) 102656.
Sene D, Ismael S, Forien M et al. Ectopic germinal center-like structures in minor salivary gland biopsy tissue predict lymphoma occurrence in patients with primary Sjӧgren’s syndrome. Arthritis Rheumatol 2018;70(9),1481-1488.
Nezos A, Gravani F, Tassidou A et al. Type I and II interferon signatures in Sjogren’s syndrome pathogenesis: contributions in distinct clinical phenotypes and Sjogren’s related lymphomagenesis. J. Autoimmun. 2015;63:47-58.
Clark GM. Prognostic factors versus predictive factors: Examples from a clinical trial of erlotinib. Mol. Oncol. 2008;1(4),406-412.
Brito-Zerón P, Kostov B, Fraile G et al. SS Study Group GEAS-SEMI. Characterization and risk estimate of cancer in patients with primary Sjӧgren’s syndrome. J. Hematol. Oncol. 2017; 10, 90.
Seror R, Bowman SJ, Brito-Zerón P et al. EULAR Sjӧgren’s syndrome disease activity index (ESSDAI): A user guide. RMD Open. 2015;1(1),000022.
Johnsen SJ, Berget E, Jonsson MV et al. Evaluation of germinal center-like structures and B cell clonality in patients with primary Sjӧgren’s syndrome with and without lymphoma. J. Rheumatol. 2014;41(11),2214-2222.
Retamozo S, Brito-Zerón P, Ramos-Casals M. Prognostic markers of lymphoma development in primary Sjogren syndrome. Lupus 2019;28,923-936.
Alunno A, Leone MC, Giacomelli R et al. Lymphoma and lymphomagenesis in primary Sjogren’s syndrome. Front. Med. 2018;5,1-7.
Brito-Zerón P, Retamozo S, Ramos-Casals M. Phenotyping Sjögren’s syndrome: towards a personalised management of the disease. Clin Exp Rheumatol 2018;36 (Suppl. 112), 198-209.
Brito-Zerón P, Acar-Denizli N, Ng W-F et al. How immunological profile drives clinical phenotype of primary Sjögren’s syndrome at diagnosis: analysis of 10,500 patients (Sjögren Big Data Project). Clin Exp Rheumatol 2018; 36 (Suppl. 112): S102-12.
Cafaro G, Bursi R, Chatzis LG et al. One year in review 2021: Sjögren’s syndrome. Clin Exp Rheumatol 2021; 39 (Suppl. 133): S3-13.
Quartuccio L, Isola M, Baldini C et al. Biomarkers of lymphoma in Sjogren’s syndrome and evaluation of the lymphoma risk in prelymphomatous conditions: results of a multicenter study. J. Autoimmun. 2014;51,75-80.
Brito-Zerón P, Retamozo S, Ramos-Casals M. Phenotyping Sjӧgren’s syndrome: Towards a personalized management of the disease. Clin. Exp. Rheumatol. 2018;36(112),198-209.
Sun R, Medeiros LJ, Young KH. Diagnostic and predictive biomarkers for lymphoma diagnosis and treatment in the era of precision medicine. Mod. Pathol. 2016;29,1118-1142.
Nocturne G, Mariette X. B cells in the pathogenesis of primary Sjogren syndrome. Nat Rev Rheumatol. 2018;14,133-145.
Dias C, Isenberg DA. Susceptibility of patients with rheumatic diseases to B-cell non-Hodgkin lymphoma. Nat. Rev. Rheumatol. 2011;7,360-368.
Sisó-Almirall A, Meijer JM, Brito-Zerón P et al. Practical guidelines for the early diagnosis of Sjögren’s syndrome in primary healthcare. Clin Exp Rheumatol 2021; 39 (Suppl. 133): S197-203.
Seror R, Ravaud P, Bowman SJ et al. EULAR Sjögren’s syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjögren’s syndrome. Ann Rheum Dis 2010; 69: 1103-9.
Baimpa E, Dahabreh IJ, Voulgarelis M, Moutsopoulos HM. Hematologic manifestations and predictors of lymphoma development in primary Sjögren syndrome: clinical and pathophysiologic aspects. Medicine (Baltimore) 2009;88:284-93.
Bautista-Vargas M, Vivas AJ, Tobon GJ. Minor salivary gland biopsy: its role in the classification and prognosis of Sjogren’s syndrome. Autoimmun. Rev. 2020;19,102690.
Quartuccio L, Isola M, Baldini C et al. Biomarkers of lymphoma in Sjogren’s syndrome and evaluation of the lymphoma risk in prelymphomatous conditions: results of a multicenter study. J. Autoimmun. 2014;51,75-80.
Brito-Zerón P, Ramos-Casals M, Bove A et al. Predicting adverse outcomes in primary Sjögren syndrome: identification of prognostic factors. Rheumatology (Oxford) 2007;46:1359-1365.
Retamozo S, Gheitasi H, Quartuccio L et al. Cryoglobulinaemic vasculitis at diagnosis predicts mortality in primary Sjögren syndrome: analysis of 515 patients. Rheumatology (Oxford) 2016; 55: 1443-51.
Retamozo S, Baldini C, Bootsma H et al. Therapeutic Recommendations for the Management of Older Adult Patients with Sjögren’s Syndrome. Drugs Aging 2021; 38: 265-84.
Sun R, Medeiros LJ, Young KH. Diagnostic and predictive biomarkers for lymphoma diagnosis and treatment in the era of precision medicine. Mod. Pathol. 2016;29,1118-1142.
Voulgarelis M, Tzioufas AG, Moutsopoulos HM. Mortality in Sjögren’s Syndrome. Clin Exp Rheumatol. 2008;26.
This work is licensed under a Creative Commons Attribution 4.0 International License.